Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...

Descripció completa

Dades bibliogràfiques
Autors principals:	Alton, E, Beekman, J, Boyd, A, Brand, J, Carlon, M, Connolly, M, Chan, M, Conlon, S, Davidson, H, Davies, J, Davies, L, Dekkers, J, Doherty, A, Gea-Sorli, S, Gill, D, Griesenbach, U, Hasegawa, M, Higgins, T, Hironaka, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Innes, J, Maher, T, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Schmidt, A, Stevenson, B, Sumner-Jones, S, Toshner, R, Tsugumine, S, Wasowicz, M, Zhu, J
Format:	Journal article
Idioma:	English
Publicat:	BMJ Publishing Group 2016

Ítems similars

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
per: Griesenbach, U, et al.
Publicat: (2016)

Moving lentiviral-based gene therapy into a first-in-man CF trial
per: Griesenbach, D, et al.
Publicat: (2015)

Towards a first-in-human trial with a pseudotyped lentivirus
per: Alton, EW, et al.
Publicat: (2020)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
per: Hyde, S, et al.
Publicat: (2015)

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
per: Griesenbach, U, et al.
Publicat: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
per: Griesenbach, U, et al.
Publicat: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
per: Griesenbach, U, et al.
Publicat: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
per: Alton, E, et al.
Publicat: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
per: Alton, E, et al.
Publicat: (2014)

Lentivirus gene therapy for autoimmune pulmonary alveolar proteinosis
per: Palau, H, et al.
Publicat: (2019)

The lung as a factory to produce secreted intrapulmonary and circulatory proteins
per: Paul-Smith, M, et al.
Publicat: (2017)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
per: Alton, E, et al.
Publicat: (2012)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
per: Alton, E, et al.
Publicat: (2012)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
per: Lund-Palau, H, et al.
Publicat: (2018)

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins
per: Paul-Smith, M, et al.
Publicat: (2018)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
per: Lund-Palau, H, et al.
Publicat: (2018)

Recombinant Sendai virus vector to evaluate vector distribution in a large animal model of lung gene transfer
per: McLachlan, G, et al.
Publicat: (2004)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
per: Pytel, K, et al.
Publicat: (2016)

Development of an immunocytochemical assay to detect human CFTR expression following gene therapy
per: Davidson, H, et al.
Publicat: (2008)

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
per: McLachlan, G, et al.
Publicat: (2011)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
per: Griesenbach, U, et al.
Publicat: (2011)

Caprine lentivirus in sheep milk and semen
per: C.C.V. Lima, et al.

An immunocytochemical assay to detect human CFTR expression following gene transfer.
per: Davidson, H, et al.
Publicat: (2009)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
per: Sergijenko, A, et al.
Publicat: (2020)

Genetic medicines for CF: Hype versus reality
per: Alton, E, et al.
Publicat: (2016)

A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution.
per: Gifford, R, et al.
Publicat: (2008)

OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
per: Sumner-Jones, S, et al.
Publicat: (2009)

Gene therapy for respiratory diseases; progress and a changing context
per: Alton, EWFW, et al.
Publicat: (2020)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
per: Gill, DR, et al.
Publicat: (2010)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep
per: Alton, E, et al.
Publicat: (2013)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
per: Alton, E, et al.
Publicat: (2013)

Discovery and analysis of the first endogenous lentivirus
per: Katzourakis, A, et al.
Publicat: (2007)

Discovery and analysis of the first endogenous lentivirus.
per: Katzourakis, A, et al.
Publicat: (2007)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
per: Davies, J, et al.
Publicat: (2009)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
per: Davies, J, et al.
Publicat: (2009)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
per: Davies, G, et al.
Publicat: (2011)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
per: Davies, J, et al.
Publicat: (2011)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
per: Alton, E, et al.
Publicat: (2013)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
per: Alton, E, et al.
Publicat: (2012)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
per: Alton, E, et al.
Publicat: (2013)